Piscataway, NJ, April 9, 2024–Camber Pharmaceuticals is pleased to announce the addition of Pantoprazole Sodium for Delayed-Release Oral Suspension to its current portfolio.
Pantoprazole Sodium for Delayed-Release Oral Suspension is indicated for:
- Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) in adults and pediatric patients five years of age and older.
- Maintenance of Healing of Erosive Esophagitis and Reduction in Relapse Rates of Daytime and Nighttime Heartburn Symptoms in adult patients with GERD.
- Long- Term Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome.
For more information regarding indications for Pantoprazole Sodium Delayed-Release Oral Suspension please click here.
Pantoprazole Sodium for Delayed-Release 40 mg Oral Suspension is available in cartons of 30 unit dose packets.
To find out more about Pantoprazole Sodium for Delayed-Release Oral Suspension, please visit https://www.camberpharma.com/pantoprazole-dr-oral-susp
